Both doses of Avastin (15 mg/kg or 7.5 mg/kg every three weeks) significantly improved PFS compared to chemotherapy alone, as assessed by trial investigators.
Although the study was not designed to compare the Avastin doses, a similar treatment effect in PFS was observed between the two arms.
USFDA-approved for two indications: 1) as a first-line treatment for metastatic colorectal cancer in combination with intravenous 5-FU-based chemotherapy and 2) as second-line treatment of patients with metastatic colorectal cancer in combination with intravenous 5-FU-based chemotherapy - Avastin® is a therapeutic antibody designed to specifically inhibit vascular endothelial growth factor (VEGF).
Inhibition of VEGF leads to interfere of the blood supply to a tumor, thus preventing the tumor's ability to grow and spread in the body (metastasize).
Read more of the clinical data from the full report.
Comment Preview